[Statin treatment in primary and secondary prevention--a statement]

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Context:

• Lipid-lowering therapy, particularly statins, is standard for secondary cardiovascular prevention.
• Debate exists regarding statin efficacy in asymptomatic individuals (primary prevention).
• Treatment discontinuation is observed, especially in French- and Italian-speaking regions of Switzerland.

Purpose:

• To clarify the role of statin therapy in primary cardiovascular prevention.
• To emphasize the importance of risk stratification for statin initiation.
• To guide treatment decisions based on individual cardiovascular risk.

Summary:

• Statins reduce LDL cholesterol, thereby decreasing cardiovascular event risk in primary prevention.
• The absolute benefit of statins is greater in individuals with higher baseline cardiovascular risk.
• Risk assessment tools are crucial for identifying appropriate candidates for statin therapy.

Impact:

• Informs clinical practice regarding statin use in primary prevention.
• Highlights the need for personalized cardiovascular risk assessment.
• Supports lifestyle interventions for low-risk populations, optimizing resource allocation.